Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of CNTA is 37 and suggests 69% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell